Close
Achema middle east
swop processing & packaging

Idifarma appoints new head of site

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Thermo Fisher Scientific to Accelerate Life Science Breakthroughs with OpenAI

WALTHAM, Mass. (October 16, 2025) – Thermo Fisher Scientific Inc....

Why Anti-Wrinkle Injections Are Gaining Popularity in Ireland

Over the past decade, Ireland has seen a significant...

Driving Excellence in Pharmaceutical Production with Advanced Pharmaceutical Cooling Systems

Introduction In pharmaceutical manufacturing, every degree matters. Process cooling is...

AstraZeneca and Daiichi Report Datroway Efficacy for TNBC

Datroway, a cancer drug developed by AstraZeneca and Daiichi...

IDIFARMA, a Spanish contract development and manufacturing organisation (CDMO) specialising in niche and highly potent products, has announced the appointment of Alfredo Gómez as its head of site.

In his new role Alfredo Gómez will be responsible for ensuring the company continues to deliver tailored development, manufacturing, and regulatory solutions to pharma companies to speed up their path to market.

With over 20 years’ experience in strategic operations within the pharmaceutical industry, Alfredo has joined the company from his most recent position at Praxis Pharmaceutical, where he was Site Director for almost a decade.

His experience and expertise will support the planned expansion of the business across European and U.S. markets and in product areas with growing demand like oncology.

Idifarma is a CDMO for niche and highly potent drugs, focusing in oral solids for oncology, and with special capabilities such as spray-drying. The company became one of only three CDMOs worldwide offering this type of spray-drying service and is planning to further invest in this technology.

Commenting on his new role Alfredo Gómez said: “Idifarma is well respected in the industry with an impressive track record of operating with niche, innovative and highly potent oral drugs, and using flexibility and specialisation to meet customer demands. I’m looking forward to contributing to its continued success and future growth.”

Latest stories

Related stories

Thermo Fisher Scientific to Accelerate Life Science Breakthroughs with OpenAI

WALTHAM, Mass. (October 16, 2025) – Thermo Fisher Scientific Inc....

Why Anti-Wrinkle Injections Are Gaining Popularity in Ireland

Over the past decade, Ireland has seen a significant...

Driving Excellence in Pharmaceutical Production with Advanced Pharmaceutical Cooling Systems

Introduction In pharmaceutical manufacturing, every degree matters. Process cooling is...

AstraZeneca and Daiichi Report Datroway Efficacy for TNBC

Datroway, a cancer drug developed by AstraZeneca and Daiichi...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »